Evidence shows weak antiviral activity and no improvement in symptom outcomes. Study: Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive ...

Researchers continue looking at existing medicine for help in the fight against the novel coronavirus, because those drugs already exist and could quickly make a big difference. The latest lead for ...

The COVID-19 pandemic has underscored the importance of understanding the various risk factors that can make certain populations more vulnerable to severe illness. Recent studies suggest that ...

Despite frequent mentions of scientific evidence, U.S. media largely ignored uncertainties and relied on non-experts, fueling public confusion during the early COVID-19 crisis. In a recent study ...

The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer.

Millions of COVID-19-associated illnesses and outpatient visits as well as thousands of hospitalizations and deaths continued to occur annually in the United States from late 2022 through 2024, ...

Add Yahoo as a preferred source to see more of our stories on Google. After a team of scientists developed a "Virtual Lab" of AI researchers, two molecules have been discovered as potential COVID-19 ...

Immune cells produced during severe COVID-19 infection may shrink tumors. The unexpected mechanism offers a new therapeutic possibility for advanced and treatment-resistant cancers. When you purchase ...